PharmaResearch Co

PharmaResearch Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaResearch Co (214450.KQ) as of Nov 2, 2026 is 214.40 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 134.56 B KRW — a change of 59.33% (higher).

EBITDA

214.40 BKRW

YoY

59.33%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaResearch Co is 2025 214.40 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaResearch Co was 2024 134.56 B KRW. It decreases by 59.33% higher compared to the previous year.

The PharmaResearch Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
12.09 B KRW
Jan 1, 2019
23.96 B KRW
Jan 1, 2020
37.57 B KRW
Jan 1, 2021
57.99 B KRW
Jan 1, 2022
68.19 B KRW
Jan 1, 2023
97.14 B KRW
Jan 1, 2024
134.56 B KRW
Jan 1, 2025
214.40 B KRW
The PharmaResearch Co EBITDA history
YEAREBITDAYoY
214.40 BKRW+59.33%
134.56 BKRW+38.52%
97.14 BKRW+42.46%
68.19 BKRW+17.58%
57.99 BKRW+54.37%
37.57 BKRW+56.81%
23.96 BKRW+98.09%
12.09 BKRW-16.93%
14.56 BKRW-0.38%
14.62 BKRW-11.76%
16.56 BKRW+42.29%
11.64 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaResearch Co Stock analysis

What does PharmaResearch Co do? PharmaResearch Co Ltd, identified by the ticker symbol 214450.KQ and ISIN KR7214450009, is a South Korean enterprise operating within the health care sector, specifically in the biotechnology industry. Headquartered in Gangneung, located in the Gangwon-Do province, the company has established itself as a specialized player in the field of marine biotechnology. The firm's core operational focus lies in the research and development of refined raw materials designed for cell and tissue regeneration. This scientific foundation supports the company's broader commercial activities, which include the production and sale of regenerated products across multiple sectors. These product categories encompass pharmaceuticals, medical devices, and cosmetics, reflecting a diverse application of its technological capabilities in health and personal care markets. The company initially entered the public markets through an initial public offering on July 24, 2015, marking a significant milestone in its corporate development and providing a platform for potential growth and capital expansion. While the primary market for its products is the domestic South Korean market, the company's strategic positioning within the biotechnology sector highlights its commitment to leveraging marine resources for advanced biological applications. Beyond its core biotechnology and manufacturing operations, PharmaResearch Co Ltd maintains a diversified business portfolio that includes venture investment and real estate leasing activities. These additional ventures contribute to the company's overall financial structure and operational breadth, although the primary emphasis remains on its scientific research and product development in the regeneration field. The company's digital presence is maintained through its official website at http://pharmaresearch.co.kr/, serving as a resource for stakeholders and partners seeking information on its ongoing projects and corporate updates. As a listed entity on the Korean market, PharmaResearch Co Ltd continues to navigate the competitive landscape of the biotechnology industry, relying on its specialized expertise in marine bio technology to drive innovation and deliver value through its regenerated products and related services. PharmaResearch Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaResearch Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaResearch Co is 214.40 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of PharmaResearch Co changed from 134.56 B KRW to 214.40 B KRW, representing a 59.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) PharmaResearch Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PharmaResearch Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — PharmaResearch Co

All Key Metrics — PharmaResearch Co